Chemomab Therapeutics Q4 EPS $(0.24) Beats $(0.40) Estimate

Chemomab Therapeutics (NASDAQ:CMMB) reported a Q4 EPS loss of $(0.24), surpassing the analyst estimate of $(0.40) by 40%. This marks a 62.5% improvement compared to a loss of $(0.64) per share in the same quarter last year.